fbpx

Year

2017
LEXINGTON, Mass., January 24, 2017 /PRNewswire/ – scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN). HFN is a clinical research initiative funded by the National Heart, Lung, and Blood Institute...
Most ESRD patients, in the last stage of chronic kidney disease, suffer from accelerated cardiovascular calcification, which correlates with higher cardiovascular risk. Cardiovascular disease is the most common cause of death in patients with ESRD and there are currently no approved therapies for the treatment of CVC. SNF472 is being developed to address this significant...
According to a new report by Aarhus University, Danish brain research is making rapid strides compared with other countries; but there’s still much to be done if we’re to rank among the world leaders Danish brain researchers are more adept than ever before at generating scientific results. In terms of volume of scientific publications, Denmark...
Neuropsychiatrist Mark Walterfang, MBBS Hons, PhD, FRANZCP, Associate Professor at The Royal Melbourne Hospital, and clinical investigator in the VTS-270 trial, said: “We are honored to lead the way in bringing to Australia this important clinical study, through which we are evaluating the intrathecal use of VTS-270 in children with NPC. There is an urgent unmet global need for...
“We are very pleased with the strong interest in this financing round from leading life science and strategic corporate investors,” said Pieter Muntendam, MD, founder, president and CEO of scPharmaceuticals. “The additional funds will support our preparation for the commercial introduction of Furoscix and the sc2Wear Infusor, as well as further development of our antibiotic pipeline...
“As we near completion of enrollment in our pivotal Phase 2b/3 clinical trial of our lead drug candidate, VTS-270, our primary goal is to advance regulatory submissions. Assuming we receive favorable responses from U.S. and European regulatory agencies, our next goal will be to rapidly provide access to VTS-270 for the children suffering from NPC...
1 7 8 9

News

Ancient DNA throws a ‘scientific hand grenade’ into the discussion about the arrival of humans in North America
23. July 2020
Danish researchers map key disease mechanism – and describe a completely new protein
20. July 2020
Five young medical students to conduct research in the US
9. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge